Key points are not available for this paper at this time.
Introduction/Background Background Secondary cytoreductive surgery is associated with improved overall survival and provides survival benefits in patients with recurrent endometrial carcinoma. This video aims to present metastasectomy along with the infrarenal vena cava, right nephrectomy, segmental small bowel resection, partial right psoas resection, and L3-L5 periosteal resection in a patient with recurrent endometrial serous cancer. Methodology A 59-year-old female with a history of serous endometrial carcinoma was treated with total laparoscopic hysterectomy and bilateral pelvic lymph node dissection in 2021, followed by chemoradiotherapy, presented with a recurrence in the paraaortic lymph nodes. She underwent cytoreductive surgery in March 2023 and subsequent chemotherapy. Later, she presented with a recurrent endometrial cancer mass in the prevertebral area, invading the vena cava. The multidisciplinary team meeting decided to perform surgery. Cytoreductive surgery with vena cava resection, right nephrectomy, segmental small bowel resection, partial right psoas resection, and L3-L5 periosteal resection was performed. Results The patient stayed at the intensive care unit for one day and was discharged without any grade 3 or 4 adverse event in the postoperative period. Conclusion Secondary cytoreduction, without any remaining disease, significantly affects survival in cases of endometrial cancer, and achieving maximal cytoreduction is crucial in specific instances. Maximal cytoreduction should be attempted by experienced gynecological oncology teams in all possible cases. Disclosures No.
Vatansever et al. (Fri,) studied this question.